EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

A randomised, double-blind, placebo-controlled crossover trial on cannabinoid-based medication for behavioural disorders in old patients with severe dementia: the study results

Federica Bianchi iD, Barbara Broers, Jules Alexandre Desmeules, Angeline Langlois, James Wampfler, François Curtin, Sophie Pautex

Age and Ageing · 03.08.2026 · 55 (8)

DOI: 10.1093/ageing/afag239 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Age and Ageing, online erschienen am 18.08.2026. Verfasst von Federica Bianchi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Palliative Medicine Division, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, GE, Switzerland. Hauptthemen laut MEDLINE: Dronabinol, Dementia, Cannabidiol, Psychomotor Agitation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Behavioural and psychological symptoms of dementia (BPSD) are frequent in patients with severe dementia and represent a major clinical challenge. Cannabinoid-based medications (CBM) have been proposed as a possible therapeutic option, but clinical evidence is still limited.

Methods

We performed a multicenter, randomised, double-blind, placebo-controlled crossover trial in five long-term care facilities in Geneva, Switzerland. Patients with severe dementia received oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) oil (1:2 ratio, up to 20 mg/40 mg daily) and placebo in two 8-week periods separated by a 1-week washout. The primary outcome was agitation measured by the Cohen–Mansfield Agitation Inventory (CMAI). Secondary outcomes included behavioural scales, pain, as-needed psychotropic medication use and safety.

Results

Twenty-five patients (average age 83 years) were randomised, and nineteen completed both study periods. No significant difference was observed between active treatment and placebo for the CMAI and other main behavioural outcomes. However, the use of pro re nata psychotropic medications was significantly lower during the active treatment period. The treatment was well tolerated, and no serious adverse events related to the study drug were observed.

Conclusions

In this real-life crossover study, THC/CBD oil did not show superiority over placebo in reducing agitation in severe dementia. However, it was safe and associated with a significant reduction in the use of as-needed psychotropic medications prescribed for behavioural and psychological symptoms of dementia. CBM may represent a possible adjunctive option in selected patients, but further studies are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DronabinolDementiaCannabidiolPsychomotor AgitationHumansDouble-Blind MethodCross-Over StudiesFemaleAged, 80 and overMaleTreatment OutcomeSeverity of Illness IndexSwitzerlandAgedTime FactorsPlant OilsLong-Term CareAge FactorsNursing Home ResidentsPsychotropic Drugs

Stichwörter der Autor:innen

behavioural and psychological symptoms of dementiacannabinoid-based medicationlong-term care facilitiesolder peoplerandomised double-blind crossover trialsevere dementia

Substanzen

DronabinolCannabidiolPlant OilsPsychotropic Drugs

Autor:innen und Institutionen

  • Palliative Medicine Division, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, GE, Switzerland.
  • Fondation pour l'accueil et l'hébergement de personnes âgées, Geneva, GE, Switzerland.
  • Faculty of Medicine, University of Geneva, Geneva, GE, Switzerland.
  • Faculty of Medicine, Department of Anesthesiology, Pharmacology, Intensive Care and Emergency Medicine, University of Geneva, Geneva, GE, Switzerland.
  • Faculty of Medicine, Department of Rehabilitation and Geriatrics, University of Geneva, Geneva, GE, Switzerland.

ORCID-Profile: Federica Bianchi

Zitieren

APA

Bianchi, F., Broers, B., Desmeules, J. A., Langlois, A., Wampfler, J., Curtin, F., & Pautex, S. (2026). A randomised, double-blind, placebo-controlled crossover trial on cannabinoid-based medication for behavioural disorders in old patients with severe dementia: the study results. Age and Ageing, 55(8). https://doi.org/10.1093/ageing/afag239

Vancouver

Bianchi F, Broers B, Desmeules JA, Langlois A, Wampfler J, Curtin F, et al. A randomised, double-blind, placebo-controlled crossover trial on cannabinoid-based medication for behavioural disorders in old patients with severe dementia: the study results. Age and Ageing. 2026;55(8). doi:10.1093/ageing/afag239

BibTeX
@article{Bianchi2026,
  author = {Bianchi, Federica and Broers, Barbara and Desmeules, Jules Alexandre and Langlois, Angeline and Wampfler, James and Curtin, François and Pautex, Sophie},
  title = {A randomised, double-blind, placebo-controlled crossover trial on cannabinoid-based medication for behavioural disorders in old patients with severe dementia: the study results},
  journal = {Age and Ageing},
  year = {2026},
  volume = {55},
  number = {8},
  doi = {10.1093/ageing/afag239}
}
Kostenlos starten →